Business Context and Reporting Period
This Form 8-K filing by Aptevo Therapeutics Inc. (APVO) was submitted on October 11, 2019, with the report date of October 16, 2019. The filing addresses a corporate governance and listing status matter regarding the company's common stock on The Nasdaq Stock Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on listing status and compliance requirements rather than financial performance data.
Material Changes
- Listing Transfer: The Company's application to transfer its listing from The Nasdaq Global Market to The Nasdaq Capital Market was approved by Nasdaq on October 16, 2019.
- Effective Date: The transfer became effective at the opening of business on October 18, 2019.
- Trading Symbol: The stock will continue to trade under the symbol "APVO."
Outlook, Risks, and Contingencies
The Company is currently non-compliant with the Nasdaq minimum bid price requirement of $1.00 per share, a condition previously disclosed in an April 23, 2019 filing.
- Compliance Period: The Company has been granted an additional 180-day period to regain compliance, extending through April 13, 2020.
- Compliance Criteria: To remain listed, the closing bid price must be at least $1.00 per share for a minimum of ten consecutive business days within this period.
- Contingency Plan: If compliance is not achieved by April 13, 2020, the Company intends to effect a reverse stock split if necessary.
- Delisting Risk: Failure to demonstrate compliance or adhere to extension terms will result in a delisting letter from Nasdaq. The Company retains the right to appeal any delisting determination to a Hearing Panel.
Investor Verification Checklist
- Verify the current trading status of APVO on The Nasdaq Capital Market.
- Monitor the daily closing bid price to assess progress toward the $1.00 minimum requirement.
- Review future filings for announcements regarding a potential reverse stock split if the April 13, 2020 deadline approaches without compliance.
- Confirm that the transfer to The Nasdaq Capital Market does not alter the trading symbol or market hours.